2024-511654-42-00招募中3 期
An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab (ONYX)
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 125
- 试验地点
- 21
- 主要终点
- Incidence of treatment-emergent adverse event (TEAEs) and serious adverse event (SAEs) by severity
研究概览
简要总结
Evaluate the long-term safety and tolerability of apitegromab in patients with Type 2 and Type 3 SMA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 主要目的
- Safety follow-up period (20 Weeks)
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 64 years（0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Informed consent document signed by the patient if the patient is legally an adult. If the patient is legally a minor, informed consent document signed by the patient's parent or legal guardian and patient's oral or written assent obtained, if applicable and in accordance with the regulatory and legal requirements of the participating location.
- •Patients who have completed the Phase 2 TOPAZ (Study SRK-015-002) trial or the Phase 3 SAPPHIRE (Study SRK-015-003) trial.
- •Estimated life expectancy >2 years from Baseline (Day 1).
- •Able to receive study drug infusions and provide blood samples through the use of a peripheral IV or a long-term IV access device that the patient has placed for reasons independent from the trial (i.e., for background medical care and not for the purpose of receiving apitegromab in the trial), throughout the trial.
- •Able to adhere to the requirements of the protocol.
- •Females of childbearing potential must have a negative pregnancy test at Baseline and agree to use at least 1 acceptable method of contraception throughout the trial and for 20 weeks after the last dose of apitegromab. Female patients who are expected to have reached reproductive maturity by the end of the trial must agree to adhere to trial-specific contraception requirements.
排除标准
- •El paciente suspendió permanentemente el tratamiento del estudio durante el ensayo preliminar (es decir, TOPAZ o SAPPHIRE)
- •Nutritional status that was not stable over the past 6 months and is not anticipated to be stable throughout the trial or medical necessity for a gastric/nasogastric feeding tube, where the majority of feeds are given by this route, as assessed by the investigator.
- •Patient is currently enrolled in any investigational drug trial other than TOPAZ or SAPPHIRE.
- •Prior history of severe hypersensitivity reaction or intolerance to SMN-targeted therapies.
- •Prior history of severe hypersensitivity reaction or intolerance to apitegromab.
- •Use of chronic daytime noninvasive ventilatory support for >16 hours daily in the 2 weeks before dosing, or anticipated to regularly receive such daytime ventilator support chronically throughout the trial.
- •Any acute or comorbid condition interfering with the well-being of the patient at the patient's last visit in TOPAZ or SAPPHIRE, including active systemic infection, the need for acute treatment, or inpatient observation due to any reason.
- •Pregnant or breastfeeding.
- •Any other condition or clinically significant laboratory result or ECG value that, in the opinion of the Investigator, may compromise safety or compliance, would preclude the patient from successful completion of the trial, or interfere with the interpretation of the results.
结局指标
主要结局
Incidence of treatment-emergent adverse event (TEAEs) and serious adverse event (SAEs) by severity
Incidence of treatment-emergent adverse event (TEAEs) and serious adverse event (SAEs) by severity
次要结局
- HFMSE total score at prespecified time points (excludes TOPAZ Cohort 1 patients)
- RULM total score at prespecified time points (excludes TOPAZ Cohort 1 patients)
- Number of WHO motor development milestones attained at prespecified time points (excludes TOPAZ Cohort 1 patients)
- RHS total score and results for 6-Minute Walk Test, 30-Second Sit-to-Stand, 10-Meter Walk/Run (from the RHS), and timed rise from floor (from the RHS) at prespecified time points (TOPAZ Cohort 1 patients only)
研究者
Bert Yao
Scientific
Scholar Rock Inc.
研究点 (21)
Loading locations...
相似试验
招募中
1 期
ong-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab.CTIS2024-511654-42-00Scholar Rock Inc.236
进行中（未招募）
1 期
ong-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of ApitegromabSpinal Muscular Atrophy (SMA)MedDRA version: 20.1Level: LLTClassification code 10041583Term: Spinal muscular atrophy, unspecifiedSystem Organ Class: 100000004850EUCTR2022-001771-14-NLScholar Rock, Inc.260
尚未招募
3 期
An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromabneuromuscular diseaseSMA10029317NL-OMON53608Scholar Rock Inc.6
进行中（未招募）
1 期
ong-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of ApitegromabSpinal Muscular Atrophy (SMA)MedDRA version: 20.1Level: LLTClassification code 10041583Term: Spinal muscular atrophy, unspecifiedSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2022-001771-14-DEScholar Rock, Inc.260
进行中（未招募）
1 期
ong-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of ApitegromabEUCTR2022-001771-14-FRScholar Rock, Inc.260